Research analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO - Get Free Report) in a report issued on Thursday. The firm set a "strong-buy" rating on the medical research company's stock.
Global Cord Blood Stock Performance
Shares of NYSE CO remained flat at $1.00 during trading hours on Thursday. The firm has a market cap of $121.55 million, a PE ratio of 1.56 and a beta of 0.16. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50. The business's 50 day simple moving average is $1.26 and its 200-day simple moving average is $1.39.
About Global Cord Blood
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Featured Stories
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
